home / stock / bti:cc / bti:cc news

BTI:CC News and Press, Bioasis Technologies Inc. From 12/14/22

Stock Information
Company Name: Bioasis Technologies Inc.
Stock Symbol: BTI:CC
Market: TSXVC
Website: bioasis.us
Menu
BTI:CC BTI:CC Quote BTI:CC Short BTI:CC News BTI:CC Articles BTI:CC Message Board
Get BTI:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
BTI:CC - Bioasis Technologies Inc. Announces Shareholder Webinar

NEW HAVEN, Conn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI) (OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal ...
BTI:CC - /C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - Resumptions

/C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - Resumptions Canada NewsWire In the news release, IIROC Trading Resumption - BTI, issued 13-Dec-2022 by Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumption...

BTI:CC - Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc

NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epi...

BTI:CC - Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022

NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on e...
BTI:CC - Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3™ platform technology for the delivery of therapeutics a...

BTI:CC - Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting remyelination Initial indications Chronic Inflammatory Degenerative Polyneuropathy, G...

BTI:CC - Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therap...
BTI:CC - Bioasis and Neuramedy Enter into Research Collaboration and License Agreement

NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics a...

BTI:CC - Bioasis Enters Into Research Collaboration With Janssen

NEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics...

Previous 10 Next 10